Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

17.84
-0.0800-0.45%
Volume:1.34M
Turnover:24.22M
Market Cap:1.58B
PE:-4.38
High:18.90
Open:18.16
Low:17.62
Close:17.92
Loading ...

Travere Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Yesterday

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Business Wire
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
18 Mar

BUZZ-Travere rises on co's marketing application for kidney disease drug

Reuters
·
17 Mar

Travere Therapeutics Shares up 4.8% After Co Submits US Marketing Application to the FDA for Kidney Disease Treatment

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS

Reuters
·
17 Mar

Travere Therapeutics Inc: Plans to Submit Amendment to Rems Snda Currently Under Review for Modification of Liver Monitoring

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Inc: Continues to Expect a Rems Modification Pdufa Target Action Date of August 28

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Inc: FDA Notified Company That Rems Monitoring for Embryo-Fetal Toxicity Is No Longer Necessary

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits Snda to FDA for Approval of Filspari® (Sparsentan) for the Treatment of Fsgs

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

GlobeNewswire
·
17 Mar

Travere Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
27 Feb

Travere Therapeutics (TVTX) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
25 Feb

Travere Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire
·
25 Feb

Guggenheim Keeps Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
23 Feb

Travere Therapeutics price target raised to $30 from $24 at TD Cowen

TipRanks
·
22 Feb